GlassScriptPhysician profile
Aaron M Bruce
NPI 1780832725
$4,994.74
in general payments reported to CMS, 2019-2025
24 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $358 · 2021: $716 · 2022: $949 · 2023: $965 · 2024: $854 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.23 |
| Education | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.74 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $434.32 | 2022-2024 | Sotyktu |
| Allergan, INC. | $342.10 | 2020-2022 | |
| Genzyme Corporation | $302.24 | 2019-2025 | |
| Pfizer INC. | $274.17 | 2019-2025 | |
| Kyowa Kirin, INC. | $264.12 | 2020-2025 | Poteligeo |
| Amgen INC. | $253.70 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $236.16 | 2019-2023 | Ilumya, Odomzo, Blu-U |
| Leo Pharma INC. | $218.17 | 2023-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $175.68 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $120.09 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $117.23 | 2021-2025 | |
| Janssen Biotech, INC. | $97.26 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $45.07 | 2022-2025 | Nemluvio |
| Biofrontera INC. | $32.86 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.80 | 2023 | Cyltezo |
| Organogenesis INC. | $29.46 | 2020 | |
| Celgene Corporation | $20.14 | 2019 | |
| Krystal Biotech INC | $19.91 | 2024 | Vyjuvek |
| Ucb, INC. | $19.25 | 2023 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $15.11 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.34 | 2023 | |
| Genentech USA, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.